Skip to main content

Advertisement

Table 5 Frequency of HPV-positive cases (Breast cancer) by clinicopathological factors

From: Presence of human papillomavirus DNA in breast cancer: a Spanish case-control study

   Number HPV+ HPV- P* OR (CI 95%)
n % n %
Lymph vascular invasion Yes 43 23 17.7% 20 16.5% 0.868 1.1 (0.6–2.1)
No 208 107 82.3% 101 83.5%   1
Lymph node metastasis Yes 104 52 40.0% 52 43.0% 0.701 0.9 (0.5–1.5)
No 147 78 60.0% 69 57.0%   1
Metastasis Yes 10 6 4.6% 4 3.3% 0.751 1.4 (0.4–5.1)
No 241 124 95.4% 117 96.7%   1
Neoadjuvant therapy Yes 33 16 12.3% 17 14.0% 0.712 0.9 (0.4–1.8)
No 218 114 87.7% 104 86.0%   1
Stage 0 25 14 10.9% 11 9.3% 0.724 1
IA 51 30 23.4% 21 17.8%   1.1 (0.4–2.9)
IB 1 1 0.8% 0 0.0%  
IIA 78 35 27.3% 43 36.4%   0.6 (0.3–1.6)
IIB 45 25 19.5% 20 16.9%   1.0 (0.4–2.6)
IIIA 32 15 11.7% 17 14.4%   0.7 (0.2–2.0)
IIIC 3 2 1.6% 1 0.8%   1.6 (0.1–20.0)
IV 11 6 4.7% 5 4.2%   0.9 (0.2–3.9)
ER 0 39 18 14.1% 21 17.5% 0.407 2.6 (0.2–27.0)
1–19% 4 1 0.8% 3 2.5%   1
≥20% 205 109 85.2% 96 80.0%   3.4 (0.3–33.1)
PgR 0 51 26 20.3% 25 20.8% 0.581 0.7 (0.3–1.7)
1–19% 37 22 17.2% 15 12.5%   1
≥20% 160 80 62.5% 80 66.7%   0.7 (0.3–1.4)
HER2 + 43 27 21.3% 16 13.8% 0.134 1.7 (0.9–3.3)
200 100 78.7% 100 86.2%   1
Ki-67 < 14 84 37 28.9% 47 39.5% 0.083 1
14–19* 71 44 34.4% 27 22.7%   2.1 (1.1–3.9)
≥ 20 91 47 36.7% 45 37.8%   1.4 (0.7–2.5)
Immunohisto-chemical subtypes LUMINAL A 88 37 29.4% 51 44.0% 0.055 1.2 (0.4–4.0)
LUMINAL B/HER2- 83 50 39.7% 33 28.4%   2.1 (0.6–7.1)
LUMINAL B/HER2+ 35 23 18.3% 12 10.3%   2.7 (0.7–10.4)
HER2+ 12 5 4.0% 7 6.0%   1
TRIPLE NEGATIVE 24 11 8.7% 13 11.2%   1.2 (0.3–4.8)
  1. ER. PgR, HER2 OR Odd Ratio, CI 95% Confidence Interval 95%, * Statistic Signification <0.05